ATE367160T1 - Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma - Google Patents
Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthmaInfo
- Publication number
- ATE367160T1 ATE367160T1 AT02787795T AT02787795T ATE367160T1 AT E367160 T1 ATE367160 T1 AT E367160T1 AT 02787795 T AT02787795 T AT 02787795T AT 02787795 T AT02787795 T AT 02787795T AT E367160 T1 ATE367160 T1 AT E367160T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr
- asthma
- treatment
- receptor antagonists
- piperazine derivatives
- Prior art date
Links
- 102000004499 CCR3 Receptors Human genes 0.000 title 1
- 108010017316 CCR3 Receptors Proteins 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33465501P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE367160T1 true ATE367160T1 (de) | 2007-08-15 |
Family
ID=23308174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02787795T ATE367160T1 (de) | 2001-11-30 | 2002-11-25 | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6906073B2 (de) |
| EP (1) | EP1453514B1 (de) |
| JP (1) | JP2005516903A (de) |
| KR (1) | KR100586131B1 (de) |
| CN (1) | CN1321115C (de) |
| AR (1) | AR037459A1 (de) |
| AT (1) | ATE367160T1 (de) |
| AU (1) | AU2002352122A1 (de) |
| BR (1) | BR0214582A (de) |
| CA (1) | CA2467966A1 (de) |
| DE (1) | DE60221275T2 (de) |
| ES (1) | ES2290346T3 (de) |
| MX (1) | MXPA04004981A (de) |
| PL (1) | PL370746A1 (de) |
| RU (1) | RU2004120063A (de) |
| WO (1) | WO2003045393A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040235855A1 (en) * | 2003-03-31 | 2004-11-25 | Bharat Lagu | Phospholipase C inhibitors for use in treating inflammatory disorders |
| US7262197B2 (en) * | 2003-03-31 | 2007-08-28 | Janssen Pharmaceutica, N.V | Phospholipase C inhibitors for use in treating inflammatory disorders |
| EP1640361B9 (de) * | 2003-06-30 | 2015-11-04 | Sumitomo Chemical Company, Limited | Asymmetrische harnstoff-verbindungen und verfahren zur herstellung von asymmetrischen verbindungen durch asymmetrische konjugat-additionsreaktion unter verwendung dieser verbindungen als katalysator |
| JP2007537275A (ja) * | 2004-05-12 | 2007-12-20 | ケモセントリックス， インコーポレイテッド | アリールスルホンアミド |
| US7517885B2 (en) * | 2005-06-29 | 2009-04-14 | Janssen Pharmaceutica N.V. | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds |
| EP1948629A1 (de) * | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituierte piperazine und piperidine als modulatoren des neuropeptid-y2-rezeptors |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| US8338426B2 (en) * | 2007-07-03 | 2012-12-25 | Janssen Pharmaceutica Nv | Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor |
| WO2010025375A1 (en) * | 2008-08-29 | 2010-03-04 | Treventis Corporation | Compositions and methods of treating amyloid disease |
| WO2010123959A2 (en) * | 2009-04-22 | 2010-10-28 | Axikin Pharmaceuticals, Inc. | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| HUE025647T2 (en) * | 2009-04-22 | 2016-04-28 | Axikin Pharmaceuticals Inc | Arylsulfonamide CCR3 antagonists |
| US11426397B2 (en) | 2017-03-26 | 2022-08-30 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 |
| EP3821947A1 (de) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterozyklische agonisten von trpml1 |
| JP2023508930A (ja) * | 2019-12-19 | 2023-03-06 | カスマ セラピューティクス， インコーポレイテッド | Ｔｒｐｍｌモジュレーター |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0592921A (ja) | 1991-05-17 | 1993-04-16 | Yamanouchi Pharmaceut Co Ltd | シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤 |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| BR9814820A (pt) * | 1997-10-14 | 2000-10-03 | Welfide Corp | Compostos de piperazina e seu uso médico |
| JP2002179651A (ja) * | 1998-06-19 | 2002-06-26 | Wakamoto Pharmaceut Co Ltd | ベンズアニリド誘導体及び医薬組成物 |
| CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1156807A4 (de) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| WO2000035454A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| DE69926919D1 (de) | 1998-12-18 | 2005-09-29 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
-
2002
- 2002-11-25 AT AT02787795T patent/ATE367160T1/de not_active IP Right Cessation
- 2002-11-25 CA CA002467966A patent/CA2467966A1/en not_active Abandoned
- 2002-11-25 EP EP02787795A patent/EP1453514B1/de not_active Expired - Lifetime
- 2002-11-25 DE DE60221275T patent/DE60221275T2/de not_active Expired - Fee Related
- 2002-11-25 BR BR0214582-0A patent/BR0214582A/pt not_active IP Right Cessation
- 2002-11-25 JP JP2003546895A patent/JP2005516903A/ja active Pending
- 2002-11-25 RU RU2004120063/04A patent/RU2004120063A/ru not_active Application Discontinuation
- 2002-11-25 KR KR1020047008311A patent/KR100586131B1/ko not_active Expired - Fee Related
- 2002-11-25 ES ES02787795T patent/ES2290346T3/es not_active Expired - Lifetime
- 2002-11-25 AU AU2002352122A patent/AU2002352122A1/en not_active Abandoned
- 2002-11-25 MX MXPA04004981A patent/MXPA04004981A/es not_active Application Discontinuation
- 2002-11-25 WO PCT/EP2002/013217 patent/WO2003045393A1/en not_active Ceased
- 2002-11-25 PL PL02370746A patent/PL370746A1/xx not_active Application Discontinuation
- 2002-11-25 CN CNB028239695A patent/CN1321115C/zh not_active Expired - Fee Related
- 2002-11-28 AR ARP020104582A patent/AR037459A1/es not_active Application Discontinuation
- 2002-11-29 US US10/307,159 patent/US6906073B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003045393A1 (en) | 2003-06-05 |
| CA2467966A1 (en) | 2003-06-05 |
| JP2005516903A (ja) | 2005-06-09 |
| CN1321115C (zh) | 2007-06-13 |
| PL370746A1 (en) | 2005-05-30 |
| AU2002352122A1 (en) | 2003-06-10 |
| MXPA04004981A (es) | 2004-08-11 |
| US6906073B2 (en) | 2005-06-14 |
| DE60221275D1 (de) | 2007-08-30 |
| KR100586131B1 (ko) | 2006-06-07 |
| AR037459A1 (es) | 2004-11-10 |
| KR20040065570A (ko) | 2004-07-22 |
| CN1599611A (zh) | 2005-03-23 |
| RU2004120063A (ru) | 2005-06-10 |
| ES2290346T3 (es) | 2008-02-16 |
| DE60221275T2 (de) | 2008-05-08 |
| BR0214582A (pt) | 2004-11-03 |
| EP1453514B1 (de) | 2007-07-18 |
| EP1453514A1 (de) | 2004-09-08 |
| US20030176441A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60221569D1 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE60133921D1 (de) | Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE50014041D1 (de) | Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis | |
| ATE374610T1 (de) | 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen | |
| DE602004010419D1 (de) | Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| ATE433978T1 (de) | 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck | |
| DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| NO20034311D0 (no) | CCR5-antagonister for behandling av AIDS | |
| ATE367160T1 (de) | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma | |
| DE50212455D1 (de) | Verwendung von Dimerdiolen | |
| DE60228317D1 (de) | N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit | |
| DE502004011551D1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| DE60120990D1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE69918541D1 (de) | Verwendung von nmda antagonisten zur behandlung des reizkolons | |
| ATE300531T1 (de) | Isonipecotamide zur behandlung von integrin vermittelten störungen | |
| DE50203046D1 (de) | Verwendung von Esterquats | |
| DE60317709D1 (de) | Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten | |
| DE60102471D1 (de) | Indolderivate zur verwendung in der behandlung von zns-störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |